The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application

Grill, 2009, Potential markers of preeclampsia—a review, Reprod Biol Endocrinol, 7, 70, 10.1186/1477-7827-7-70 Duley, 2009, The global impact of pre-eclampsia and eclampsia, Semin Perinatol, 33, 130, 10.1053/j.semperi.2009.02.010 Redman, 2005, Latest advances in understanding preeclampsia, Science, 308, 1592, 10.1126/science.1111726 Chan, 2005, Proteinuria in pre-eclampsia: how much matters?, BJOG, 112, 280, 10.1111/j.1471-0528.2004.00395.x Sibai, 2003, Diagnosis and management of gestational hypertension and preeclampsia, Obstet Gynecol, 102, 181, 10.1016/S0029-7844(03)00475-7 Wikstrom, 2008, Early postpartum changes in circulating pro- and anti-angiogenic factors in early-onset and late-onset pre-eclampsia, Acta Obstet Gynecol Scand, 87, 146, 10.1080/00016340701819262 Stella, 2006, Preeclampsia: diagnosis and management of the atypical presentation, J Matern Fetal Neonatal Med, 19, 381, 10.1080/14767050600678337 Wagner, 2004, Diagnosis and management of preeclampsia, Am Fam Physician, 70, 2317 Weinstein, 1982, Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy, Am J Obstet Gynecol, 142, 159, 10.1016/S0002-9378(16)32330-4 Marik, 2009, Hypertensive disorders of pregnancy, Postgrad Med, 121, 69, 10.3810/pgm.2009.03.1978 Bujold, 2009, Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis, J Obstet Gynaecol Can, 31, 818, 10.1016/S1701-2163(16)34300-6 Alfonso, 2009, Preventing preeclampsia: the evidence on nutrients, Nurs Womens Health, 13, 419, 10.1111/j.1751-486X.2009.01460.x Barton, 2008, Prediction and prevention of recurrent preeclampsia, Obstet Gynecol, 112, 359, 10.1097/AOG.0b013e3181801d56 Wilson, 1968, Principles and practice of mass screening for disease, Bol Oficina Sanit Panam, 65, 281 Verlohren, 2010, An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia, Am J Obstet Gynecol, 202, 161.e1, 10.1016/j.ajog.2009.09.016 Hahn, 2006, Disturbances in placental immunology: ready for therapeutic interventions?, Springer Semin Immunopathol, 27, 477, 10.1007/s00281-006-0016-5 Huppertz, 2007, The feto-maternal interface: setting the stage for potential immune interactions, Semin Immunopathol, 29, 83, 10.1007/s00281-007-0070-7 Jauniaux, 2006, Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution, Hum Reprod Update, 12, 747, 10.1093/humupd/dml016 Hung, 2002, Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia, Circ Res, 90, 1274, 10.1161/01.RES.0000024411.22110.AA Soleymanlou, 2005, Molecular evidence of placental hypoxia in preeclampsia, J Clin Endocrinol Metab, 90, 4299, 10.1210/jc.2005-0078 Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, 649, 10.1172/JCI17189 Roberts, 1989, Preeclampsia: an endothelial cell disorder, Am J Obstet Gynecol, 161, 1200, 10.1016/0002-9378(89)90665-0 Huppertz, 2008, Placental origins of preeclampsia: challenging the current hypothesis, Hypertension, 51, 970, 10.1161/HYPERTENSIONAHA.107.107607 Roberts, 2009, The two stage model of preeclampsia: variations on the theme, Placenta, 30, S32, 10.1016/j.placenta.2008.11.009 Action on Pre-eclampsia, 2004 National Institute for Clinical Excellence, 2008 ACOG Committee on Practice Bulletins, 2002, ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002, Obstet Gynecol, 99, 159 Carty, 2008, Novel biomarkers for predicting preeclampsia, Trends Cardiovasc Med, 18, 186, 10.1016/j.tcm.2008.07.002 Fayyad, 2005, Prediction and prevention of preeclampsia and IUGR, Early Hum Dev, 81, 865, 10.1016/j.earlhumdev.2005.09.005 Than, 2008, Prediction of preeclampsia—a workshop report, Placenta, 29, S83, 10.1016/j.placenta.2007.10.008 Huppertz, 2005, Vascular biology in implantation and placentation, Angiogenesis, 8, 157, 10.1007/s10456-005-9007-8 Demir, 2007, Vasculogenesis and angiogenesis in the early human placenta, Acta Histochem, 109, 257, 10.1016/j.acthis.2007.02.008 Valdes, 2009, Vasodilator factors in the systemic and local adaptations to pregnancy, Reprod Biol Endocrinol, 7, 79, 10.1186/1477-7827-7-79 Lam, 2005, Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia, Hypertension, 46, 1077, 10.1161/01.HYP.0000187899.34379.b0 Signore, 2006, Circulating angiogenic factors and placental abruption, Obstet Gynecol, 108, 338, 10.1097/01.AOG.0000216014.72503.09 Chafetz, 2007, First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction, Am J Obstet Gynecol, 197, 35, 10.1016/j.ajog.2007.02.025 Spencer, 2008, Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia, Prenat Diagn, 28, 7, 10.1002/pd.1890 Venkatesha, 2006, Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, 12, 642, 10.1038/nm1429 Levine, 2006, Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, 355, 992, 10.1056/NEJMoa055352 Staff, 2007, Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia, Am J Obstet Gynecol, 197, 176.e1, 10.1016/j.ajog.2007.03.036 Levine, 2004, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, 350, 672, 10.1056/NEJMoa031884 Hertig, 2004, Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia, Clin Chem, 50, 1702, 10.1373/clinchem.2004.036715 McKeeman, 2004, Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop, Am J Obstet Gynecol, 191, 1240, 10.1016/j.ajog.2004.03.004 Tsatsaris, 2003, Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences, J Clin Endocrinol Metab, 88, 5555, 10.1210/jc.2003-030528 Woolcock, 2008, Soluble Flt-1 as a diagnostic marker of pre-eclampsia, Aust N Z J Obstet Gynaecol, 48, 64, 10.1111/j.1479-828X.2007.00804.x Koga, 2003, Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia, J Clin Endocrinol Metab, 88, 2348, 10.1210/jc.2002-021942 Chaiworapongsa, 2005, Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia, J Matern Fetal Neonatal Med, 17, 3, 10.1080/14767050400028816 Shibata, 2005, Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor, J Clin Endocrinol Metab, 90, 4895, 10.1210/jc.2004-1955 Kim, 2007, Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia, J Korean Med Sci, 22, 873, 10.3346/jkms.2007.22.5.873 Torry, 1998, Preeclampsia is associated with reduced serum levels of placenta growth factor, Am J Obstet Gynecol, 179, 1539, 10.1016/S0002-9378(98)70021-3 Taylor, 2003, Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies, Am J Obstet Gynecol, 188, 177, 10.1067/mob.2003.111 Reuvekamp, 1999, Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia, Br J Obstet Gynaecol, 106, 1019, 10.1111/j.1471-0528.1999.tb08107.x Livingston, 2000, Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia, Am J Obstet Gynecol, 183, 1554, 10.1067/mob.2000.108022 Livingston, 2001, Placenta growth factor is not an early marker for the development of severe preeclampsia, Am J Obstet Gynecol, 184, 1218, 10.1067/mob.2001.113877 Tjoa, 2001, Plasma placenta growth factor levels in midtrimester pregnancies, Obstet Gynecol, 98, 600, 10.1016/S0029-7844(01)01497-1 Levine, 2005, Urinary placental growth factor and risk of preeclampsia, JAMA, 293, 77, 10.1001/jama.293.1.77 Sunderji, 2010, Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study, Am J Obstet Gynecol, 202, 40, 10.1016/j.ajog.2009.07.025 De Vivo, 2008, PlGF and sFlt-1 as markers for predicting pre-eclampsia, Acta Obstet Gynecol Scand, 87, 837, 10.1080/00016340802253759 Ohkuchi, 2010, Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia, Hypertens Res, 10.1038/hr.2010.15 Stepan, 2007, Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion, Hypertension, 49, 818, 10.1161/01.HYP.0000258404.21552.a3 Masuyama, 2010, Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia, BJOG, 117, 314, 10.1111/j.1471-0528.2009.02453.x Kusanovic, 2009, A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia, J Matern Fetal Neonatal Med, 22, 1021, 10.3109/14767050902994754 Lim, 2008, Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors, Obstet Gynecol, 111, 1403, 10.1097/AOG.0b013e3181719b7a Chien, 2000, How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview, BJOG, 107, 196, 10.1111/j.1471-0528.2000.tb11690.x Cnossen, 2008, Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis, CMAJ, 178, 701, 10.1503/cmaj.070430 Bower, 1993, Improved prediction of preeclampsia by two-stage screening of uterine arteries using the early diastolic notch and color Doppler imaging, Obstet Gynecol, 82, 78 Stepan, 2008, Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion, Am J Obstet Gynecol, 198, 175, 10.1016/j.ajog.2007.08.052 Crispi, 2008, Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction, Ultrasound Obstet Gynecol, 31, 303, 10.1002/uog.5184 Espinoza, 2007, Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor, Am J Obstet Gynecol, 196, 326, 10.1016/j.ajog.2006.11.002 Cnossen, 2009, Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal, Acta Obstet Gynecol Scand, 88, 758, 10.1080/00016340903008953 Duley, 2006, Management of pre-eclampsia, BMJ, 332, 463, 10.1136/bmj.332.7539.463 Roberts, 2001, Pathogenesis and genetics of pre-eclampsia, Lancet, 357, 53, 10.1016/S0140-6736(00)03577-7 Bellamy, 2007, Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis, BMJ, 335, 974, 10.1136/bmj.39335.385301.BE McDonald, 2008, Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses, Am Heart J, 156, 918, 10.1016/j.ahj.2008.06.042 Sanderson, 2000, Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients, Am J Obstet Gynecol, 183, 1504, 10.1067/mob.2000.107357 Bode, 2001, Perinatal regionalization and neonatal mortality in North Carolina, 1968–1994, Am J Obstet Gynecol, 184, 1302, 10.1067/mob.2001.114484 Obladen, 1994, Differences in morbidity and mortality according to type of referral of very low birthweight infants, J Perinat Med, 22, 53, 10.1515/jpme.1994.22.1.53 Roche Diagnostics GmbH, 2008 Roche Diagnostics GmbH, 2008 International Academy of Perinatal Medicine, 2010, The prediction and prevention of preterm birth and its consequences: an unmet challenge to perinatal medicine, science and society, J Perinat Med, 38, 1, 10.1515/jpm.2010.015 Thadhani, 2004, First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia, J Clin Endocrinol Metab, 89, 770, 10.1210/jc.2003-031244